Advertisement

18F-FET

  • Giorgio TregliaEmail author
  • Barbara Muoio
  • Luca Giovanella
Chapter

Abstract

18F-FET is a radiolabelled amino acid that may be used as PET radiopharmaceutical in neuro-oncology. 18F-FET PET has been demonstrated to be useful in the differential diagnosis between brain tumours and non-neoplastic lesions and between low-grade and high-grade gliomas. Integration of 18F-FET PET into surgical planning allows better delineation of the extent of resection beyond margins visible with standard MRI. For biopsy planning, 18F-FET PET is particularly useful in identifying malignant foci within non-contrast-enhancing gliomas. 18F-FET PET may also improve the radiation therapy planning in patients with gliomas. This metabolic imaging method may be useful to evaluate treatment response in patients with gliomas and it improves the differential diagnosis between brain tumours recurrence and post-treatment changes. Furthermore, 18F-FET PET may provide useful prognostic information in high-grade gliomas.

Overall, based on literature data 18F-FET PET may provide additional diagnostic information compared to standard MRI in neuro-oncology.

Keywords

18F-FET Fluoroethyltyrosine PET Brain tumours Glioma Neuro-oncology 

Abbreviations

18F-FDG

Fluorine-18 fluorodeoxyglucose

18F-FDOPA

Fluorine-18 fluorodihydroxyphenylalanine

18F-FET

Fluorine-18 fluoroethyltyrosine

18F-FLT

Fluorine-18 fluorothymidine

CT

Computed tomography

EANO

European Association for Neuro-Oncology

LBR

Lesion-to-background ratio

MBq

MegaBecquerel

MRI

Magnetic resonance imaging

PET

Positron emission tomography

RANO

Response Assessment in Neuro-Oncology (RANO)

Sv

Sievert

Notes

Acknowledgements

Conflicts of Interest: The authors declare that they have no conflicts of interest.

References

  1. 1.
    Hamacher K, Coenen HH. Efficient routine production of the 18F-labelled amino acid O-2-18F fluoroethyl-L-tyrosine. Appl Radiat Isot. 2002;57(6):853–6.CrossRefGoogle Scholar
  2. 2.
    Wester HJ, Herz M, Weber W, et al. Synthesis and radiopharmacology of O-(2-[18F]fluoroethyl)-L-tyrosine for tumor imaging. J Nucl Med. 1999;40(1):205–12.PubMedGoogle Scholar
  3. 3.
    Heiss P, Mayer S, Herz M, et al. Investigation of transport mechanism and uptake kinetics of O-(2-[18F]fluoroethyl)-L-tyrosine in vitro and in vivo. J Nucl Med. 1999;40(8):1367–73.PubMedGoogle Scholar
  4. 4.
    Pauleit D, Floeth F, Herzog H, et al. Whole-body distribution and dosimetry of O-(2-[18F]fluoroethyl)-L-tyrosine. Eur J Nucl Med Mol Imaging. 2003;30(4):519–24.CrossRefGoogle Scholar
  5. 5.
    Tang G, Wang M, Tang X, et al. Pharmacokinetics and radiation dosimetry estimation of O-(2-[18F]fluoroethyl)-L-tyrosine as oncologic PET tracer. Appl Radiat Isot. 2003;58(2):219–25.CrossRefGoogle Scholar
  6. 6.
    Vander Borght T, Asenbaum S, Bartenstein P, et al. EANM procedure guidelines for brain tumour imaging using labelled amino acid analogues. Eur J Nucl Med Mol Imaging. 2006;33(11):1374–80.CrossRefGoogle Scholar
  7. 7.
    Muoio B, Giovanella L, Treglia G. Recent developments of 18F-FET PET in neuro-oncology. Curr Med Chem. 2018;25(26):3061–73.CrossRefGoogle Scholar
  8. 8.
    Albert NL, Weller M, Suchorska B, et al. Response Assessment in Neuro-Oncology Working Group and European Association for Neuro-Oncology recommendations for the clinical use of PET imaging in gliomas. Neuro Oncol. 2016;18(9):1199–208.CrossRefGoogle Scholar
  9. 9.
    Dunet V, Rossier C, Buck A, et al. Performance of 18F-fluoro-ethyl-tyrosine (18F-FET) PET for the differential diagnosis of primary brain tumor: a systematic review and metaanalysis. J Nucl Med. 2012;53(2):207–14.CrossRefGoogle Scholar
  10. 10.
    Heinzel A, Stock S, Langen KJ, et al. Cost-effectiveness analysis of FET PET-guided target selection for the diagnosis of gliomas. Eur J Nucl Med Mol Imaging. 2012;39(7):1089–96.CrossRefGoogle Scholar
  11. 11.
    Munck Af Rosenschold P, Costa J, Engelholm SA, et al. Impact of [18F]-fluoro-ethyl-tyrosine PET imaging on target definition for radiation therapy of high-grade glioma. Neuro Oncol. 2015;17(5):757–63.CrossRefGoogle Scholar
  12. 12.
    Muoio B, Treglia G, Reinert M, et al. Diagnostic performance of static 18F-fluoroethyl-L-tyrosine positron emission tomography parameters to differentiate recurrent brain tumours from non-neoplastic treatment-related changes: a meta-analysis. Neuro Oncol. 2016;18.(Suppl 4:iv9.CrossRefGoogle Scholar
  13. 13.
    Gempt J, Bette S, Ryang YM, et al. 18F-fluoro-ethyl-tyrosine positron emission tomography for grading and estimation of prognosis in patients with intracranial gliomas. Eur J Radiol. 2015;84(5):955–62.CrossRefGoogle Scholar
  14. 14.
    Henriksen OM, Larsen VA, Muhic A, et al. Simultaneous evaluation of brain tumour metabolism, structure and blood volume using [(18)F]-fluoroethyltyrosine (FET) PET/MRI: feasibility, agreement and initial experience. Eur J Nucl Med Mol Imaging. 2016;43(1):103–12.CrossRefGoogle Scholar
  15. 15.
    Grosu AL, Astner ST, Riedel E, et al. An interindividual comparison of O-(2-[18F]fluoroethyl)-L-tyrosine (FET)- and L-[methyl-11C]methionine (MET)-PET in patients with brain gliomas and metastases. Int J Radiat Oncol Biol Phys. 2011;81(4):1049–58.CrossRefGoogle Scholar
  16. 16.
    Roelcke U, Bruehlmeier M, Hefti M, et al. F-18 choline PET does not detect increased metabolism in F-18 fluoroethyltyrosine-negative low-grade gliomas. Clin Nucl Med. 2012;37(1):e1–3.CrossRefGoogle Scholar
  17. 17.
    Jeong SY, Lim SM. Comparison of 3′-deoxy-3′-[18F]fluorothymidine PET and O-(2-[18F]fluoroethyl)-L-tyrosine PET in patients with newly diagnosed glioma. Nucl Med Biol. 2012;39(7):977–81.CrossRefGoogle Scholar
  18. 18.
    Nowosielski M, DiFranco MD, Putzer D, et al. An intra-individual comparison of MRI, [18F]-FET and [18F]-FLT PET in patients with high-grade gliomas. PLoS One. 2014;9(4):e95830.CrossRefGoogle Scholar
  19. 19.
    Kratochwil C, Combs SE, Leotta K, et al. Intra-individual comparison of 18F-FET and 18F-DOPA in PET imaging of recurrent brain tumors. Neuro Oncol. 2014;16(3):434–40.CrossRefGoogle Scholar
  20. 20.
    Lapa C, Linsenmann T, Monoranu CM, et al. Comparison of the amino acid tracers 18F-FET and 18F-DOPA in high-grade glioma patients. J Nucl Med. 2014;55(10):1611–6.CrossRefGoogle Scholar
  21. 21.
    Dunet V, Pomoni A, Hottinger A, et al. Performance of 18F-FET versus 18F-FDG-PET for the diagnosis and grading of brain tumors: systematic review and meta-analysis. Neuro Oncol. 2016;18(3):426–34.CrossRefGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2020

Authors and Affiliations

  • Giorgio Treglia
    • 1
    • 2
    • 3
    Email author
  • Barbara Muoio
    • 4
  • Luca Giovanella
    • 1
  1. 1.Imaging Institute of Southern SwitzerlandEnte Ospedaliero CantonaleBellinzona and LuganoSwitzerland
  2. 2.Health Technology Assessment Unit, General DirectorateEnte Ospedaliero CantonaleBellinzonaSwitzerland
  3. 3.Department of Nuclear Medicine and Molecular ImagingUniversity Hospital of Lausanne and University of LausanneLausanneSwitzerland
  4. 4.Oncology Institute of Southern Switzerland, Ente Ospedaliero CantonaleBellinzonaSwitzerland

Personalised recommendations